BofA raises target for Qiagen stock to USD 50.00

Published on 10/13/2026 at 14:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 535.04 million in the second quarter. Qiagen stock costs EUR 40.63 on October 13, 2026, up 0.23 percent versus the October 12 Xetra close.

Array

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

BofA raised its Qiagen target to USD 50.00 from USD 49.00 on October 9, 2026, while keeping a Buy rating. The target lies 10.35 percent above the USD 45.31 NYSE price on October 12, 2026. At Lang & Schwarz, Qiagen stock was trading at EUR 40.63 on October 13, 2026 at 2:19 p.m. CEST, 0.23 percent above the Xetra close of October 12, 2026 at EUR 40.54.

Second-quarter revenue stays stable

For the second quarter of 2026, Qiagen reported revenue of USD 535.0 million, flat year over year. Diluted earnings per share reached USD 0.50, up from USD 0.44 in the second quarter of 2025, according to Simply Wall St. The combination of flat revenue and higher earnings per share puts operating efficiency ahead of top-line acceleration in the latest reported quarter.

Stock remains below its yearly high

The USD 45.31 NYSE price on October 12, 2026 stood 21.64 percent below the 52-week high of USD 57.82 and 39.29 percent above the 52-week low of USD 32.53. Trading volume was 1,171,567 shares against an average of 2,515,001, while the market capitalization was USD 9.3 billion.

Valuation trails the peer group

Qiagen's price-to-earnings ratio was 23.24 on October 12, 2026. That multiple was below Bio-Rad Laboratories at 44.17 and Danaher at 39.29, although peer scale differed sharply.

Comparison with peers

Qiagen (NYSE, USD): plus 0.23 percent, P/E 23.24, market capitalization USD 9.3 billion
Bio-Rad Laboratories (NYSE, USD): minus 0.48 percent, P/E 44.17, market capitalization USD 9.8 billion
Danaher (NYSE, USD): plus 0.63 percent, P/E 39.29, market capitalization USD 155.5 billion

Price and target in view

Markets Insider reported on October 9, 2026 that BofA expects the life science tools sector to benefit from a further re-rating, while also noting that valuations already price in a market recovery. The USD 1.00 target increase is therefore paired with a clear valuation caveat rather than a change in the latest reported revenue trend.

The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.